Skip to content
All news
Analysis

Morgan Stanley Downgrades Adobe: Execution Risks and AI Monetization Concerns

Morgan Stanley downgraded Adobe (ADBE) from neutral to sell, citing rising execution risks as the company navigates multiple strategic transitions. The firm sees cleaner growth and better AI monetization opportunities elsewhere.

July 21, 2026
2 min read
Source: Stocktwits
Share:

Morgan Stanley downgraded Adobe (ADBE) from "neutral" to "sell," sending the stock lower in pre-market trading. The downgrade comes amid concerns that the company faces rising execution risks as it manages several strategic transitions simultaneously.

Rating Change

Previously, the rating was "neutral" with an undisclosed price target. After the downgrade, the rating is "sell" with a new lower price target. (Exact price target figures were not disclosed in the source.)

Analyst Rationale

The analyst believes Adobe faces increasing execution risks because it is handling multiple strategic shifts at once, including the transition to cloud subscriptions and accelerating AI product rollouts. Additionally, the analyst sees "cleaner growth and AI monetization" in other companies, making Adobe relatively less attractive.

Context

Adobe (ADBE) has been under pressure in recent months as its revenue growth slowed compared to other tech firms capitalizing on AI. Other analysts are divided; some believe Adobe's creative tools remain essential, while others fear competition from generative AI tools.

What to Make of It

Morgan Stanley's downgrade reflects growing concern about Adobe's ability to deliver expected AI-driven growth in the near term. Investors should watch the next quarterly results to gauge progress on strategic execution.

Frequently Asked Questions

Due to rising execution risks from multiple strategic transitions and seeing better AI monetization opportunities elsewhere.

Found this useful? Share it

Share:
This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.